Welcome to: Rimonabant Information Source (rimonabant fda june 2007)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

Potential? obesity drug Acomplia (rimonabant) is set to be tested as a remedy for clogged arteries and heart disease. All the drug has been shown to help people lose weight and stop smoking (C & I 2004.18, 8). Now the developer, Sanofi-Aventis, says plans for the unexpected consequences of the increasing good cholesterol, are .. Most Popular 3 Questions No Job Seeker Ever Wants To Be Asked? 10 jobs that pay $ 30 An Hour Employee Incentive Program - For the best value for money 13 Job Interview Mistakes to Avoid 5 Regular Mistakes In Public Speaking Read the rest of this article with a free trial version at High Beam Research ..

Rimonabant Pricelist

Please wait while we load the price list
The drug helps in decreasing the over activity of EC (endocannabinoid) system. EC is responsible is a physiological system which plays an important role in controlling energy balance and body weight. Nausea, headache, dizziness and depression are some of the common side effects associated with the intake of Rimonabant. However, the side effects are mild and are for short period only. A person should always consult a doctor before going for the drug. A doctor is the right person to decide what will work out for him. Children, breast feeding mothers and pregnant women should consult a doctor before taking the drug. Persons with heart ailments, diabetes, asthma, allergy or blood pressure should tell their doctor prior to the medication of Rimonabant (Acomplia). Visit http://www.acompliarimonabantuk.co.uk for more..

This latest report, Rimonabant: The first of the Cannabinoid blockbusters, forecasts the cannabinoid market in 2007 to generate $709 million in sales. This has grown 45% from 2006, when it was generating $386 million. The profile of the market will be raised considerably with Rimonabant, by Sanofi-Aventis, used to treat obesity and set to reach impressive sales in its first few years. Rimonabant, branded Acomplia and Zimulti (US), has now been approved for sale in all 25 countries of the European Union by the European Commission. Marinol®, Cesamet®, Sativex ® and Rimonabant are all commercially-marketed cannabinoids. They treat a variety of conditions from weight-loss to pain relief. The introduction of cannabinoids into the pharmaceutical marketplace has begun, and attitudes to the drugs are changing.